Carboxymethylcellulose

Overview

Carboxymethylcellulose is a cellulose derivative that consists of the cellulose backbone made up of glucopyranose monomers and their hydroxyl groups bound to carboxymethyl groups. It is added in food products as a viscosity modifier or thickener and emulsifier. It is also one of the most common viscous polymers used in artificial tears, and has shown to be effective in the treatment of aqueous tear-deficient dry eye symptoms and ocular surface staining . The viscous and mucoadhesive properties as well as its anionic charge allow prolonged retention time in the ocular surface . Sodium carboxymethylcellulose is the most commonly used salt.

Indication

Indicated for the symptomatic relief of burning, irritation and discomfort of the eyes due to dryness or exposure to wind or sun.

Associated Conditions

Dry Eyes
Ocular Irritation

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome	2022/03/23	NCT05292755	Phase 4	Completed	University of Florida
Effects of Stulln and Accommodative Training	2021/11/04	NCT05107791	Phase 1	Withdrawn	Pacific University
Post Intravitreal Injection Topical NSAID vs. Patching	2019/04/17	NCT03918590	Phase 4	UNKNOWN	The New York Eye & Ear Infirmary
Dry Eye Disease Study With Brimonidine	2018/02/01	NCT03418727	Phase 2	Completed	Ocugen
Efficacy and Safety of Iota-Carrageenan Eye Drops (NCX-4240)	2017/01/04	NCT03009799	Phase 2	Withdrawn	NicOx
Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating Drops	2016/05/02	NCT02758327	Phase 4	Completed	Koffler Vision Group
A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.	2015/09/18	NCT02553772	Phase 3	Completed	Allergan
Echothiophate Iodide for the Prevention of Progression of Myopia	2015/09/09	NCT02544529	Phase 4	Withdrawn	Danbury Eye Physicians & Surgeons, PC
A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief	2015/05/27	NCT02455050	Phase 3	Completed	Allergan
Healing of Persistent Epithelial Defects	2015/03/24	NCT02395952	Not Applicable	Withdrawn	Milton S. Hershey Medical Center

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
REFRESH OPTIVE FUSION SENSITIVE	Allergan, Inc.	02450534	Solution - Ophthalmic	0.5 % / W/V	4/26/2016
REFRESH OPTIVE GEL DROPS	Abbvie Corporation	02463652	Solution - Ophthalmic	1 % / W/V	7/28/2017
REFRESH CELLUVISC	Abbvie Corporation	00870153	Drops - Ophthalmic	1 % / W/V	12/31/1991
CLEAR EYES FOR DRY EYES	prestige brands inc	02286858	Solution - Ophthalmic	1.0 %	3/26/2008
REFRESH CONTACTS	Abbvie Corporation	02304015	Solution - Ophthalmic	0.5 % / W/V	3/13/2008
PRESERVATIVE-FREE THERA TEARS LUBRICANT EYE DROPS	medtech products inc	02242082	Drops - Ophthalmic	0.25 % / W/V	6/1/2002
NUTRIGEL CAP 300MG	carmaran ltée	00658014	Capsule - Oral	300 MG	12/31/1987
REFRESH OPTIVE ADVANCED SENSITIVE	Abbvie Corporation	02425815	Emulsion - Ophthalmic	0.5 % / W/W	10/14/2014
SALIVART AER	all star sales and service ltd.	00894397	Aerosol - Oral	1 %	12/31/1990
REFRESH PLUS	Abbvie Corporation	02049260	Drops - Ophthalmic	0.5 % / W/V	1/31/2000

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

SpyGlass Pharma Appoints Veteran Pharmaceutical Executive as Chief R&D Officer to Advance Intraocular Drug Delivery Platform

4 months ago

• SpyGlass Pharma has appointed Chetan Pujara, Ph.D., as Chief Research & Development Officer to lead the company's proprietary intraocular drug delivery platform into Phase 3 trials. • Dr. Pujara brings over 20 years of leadership experience in pharmaceutical development and has contributed to market-leading products including Ozurdex®, Durysta™, and other ophthalmic therapies. • The SpyGlass Drug Delivery Platform with bimatoprost is designed to deliver three years of sustained medication release for glaucoma patients, with potential applications in additional ophthalmic conditions.

Help Us Improve

Your feedback helps us provide better drug information and insights.

AI-Powered Research

Premium Access